Albeit for other, mostly oncological indications, compounds targeting the identified pathways are approved or are currently being evaluated in clinical trials, such as the VEGFR2 inhibitor apatinib (Miao et al., 2018), the TrkA kinase inhibitor CT327, which lessens itching in psoriasis patients as a topical formulation (Roblin et al., 2015), the PI3Kα/δ inhibitor copanlisib (Dreyling et al., 2017), and several MEK inhibitors (Sarkisian & Davar, 2018). This evidence concerns the gene KDR and psoriasis.